AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
At close
$16.06
+$0.04 (+0.24%) Close
Pre-market$16.03
−$0.03 (−0.18%) 3:18 AM ET
Prev closePrevC$16.02
OpenOpen$15.90
Day highHigh$16.06
Day lowLow$15.90
VolumeVol1,982,883
Avg volAvgVol1,758,738
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$2.46B
P/E ratio
-40.15
FY Revenue
$276.98M
EPS
-0.40
Gross Margin
74.24%
Sector
Healthcare
AI report sections
MIXED
ADPT
Adaptive Biotechnologies Corporation
Adaptive Biotechnologies combines rapid share-price appreciation and bullish technical signals with ongoing operating losses and negative free cash flow. The stock is trading near the upper end of its 52-week range with improving revenue and earnings trends but also meaningful short interest and competitive pressures in its core MRD market. Overall positioning reflects a constructive intermediate-term trend balanced against execution, cash-flow, and competitive risks.
Pfizer Faces Another Quiet Year As Patent Losses Cloud 2026 Outlook: Analyst
Bank of America expects Pfizer's 2026 financial outlook to remain flat, with challenges from ongoing patent exclusivity losses and limited pipeline catalysts. The company is focusing on areas like obesity treatments, antibody-drug conjugates, and pneumococcal franchise development.
Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting
Adaptive Biotechnologies presented 90 abstracts at the ASH Annual Meeting, highlighting its clonoSEQ® test's effectiveness in guiding treatment interventions across multiple blood cancer types, demonstrating precision in measurable residual disease (MRD) monitoring.
Company showcased extensive clinical research across multiple cancer types, demonstrated leadership in MRD testing, and presented data supporting treatment decision-making with its clonoSEQ® technology
NegativeBenzinga• Vandana Singh
Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?
Adaptive Biotechnologies' stock dropped after Natera acquired Foresight Diagnostics for $275 million upfront, raising competitive concerns in the blood-cancer minimal residual disease (MRD) market.
ADPTNTRAABTEXASacquisitiononcologyMRDdiagnostics
Sentiment note
Stock dropped 12.63% due to potential competitive threat from Natera's acquisition and reduced M&A speculation after previous Abbott-Exact Sciences deal
PositiveThe Motley Fool• Eric Volkman
Why Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday
Adaptive Biotechnologies reported strong Q2 2025 results with 36% revenue growth, primarily driven by minimal residual disease (MRD) business. The company beat analyst expectations and raised its MRD revenue guidance for 2025.
Demonstrated strong revenue growth of 36%, beat analyst estimates, narrowed net loss, raised revenue guidance for MRD business, and saw stock price increase by almost 6% following earnings report
U.S. Minimal Residual Disease Testing Market Trends Analysis Report 2025-2033 | Integration with Personalized Medicines, & Rising Incidence and Prevalence of Hematological Malignancies Fueling Growth
The U.S. minimal residual disease testing market is projected to reach $2020 million by 2033, growing at a 9.38% CAGR, driven by rising cancer rates and advancements in precision medicine technologies like NGS and flow cytometry.
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers
Adaptive Biotechnologies presented new data on the use of its clonoSEQ test for measurable residual disease (MRD) assessment in various blood cancer types at major medical conferences.
The article highlights the company's new data presentations on the clinical utility of its clonoSEQ MRD test, which is being widely adopted in the management of various blood cancers.
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - Precision Medicine and Early Relapse Detection Drive MRD Testing Demand Worldwide
The Minimal Residual Disease (MRD) Testing Market is expected to grow at a CAGR of 11.18% from 2025 to 2030, driven by advancements in diagnostic technologies and the increasing focus on precision medicine and early relapse detection.
The article highlights Adaptive Biotechnologies Corporation as one of the leading companies driving innovation in the MRD testing market.
PositiveBenzinga• Prnewswire
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year
The article discusses the promising developments in cancer research, including new therapies and innovative technologies, and highlights recent updates from several biotech companies working on cutting-edge cancer treatments.
ONCYADPTNEOELEVcanceroncologybiotechimmunotherapy
Sentiment note
The article discusses Adaptive Biotechnologies' collaboration with NeoGenomics to expand access to Adaptive's clonoSEQ test for minimal residual disease (MRD) monitoring in blood cancers, which can help oncologists develop more personalized treatment plans.
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
Adaptive Biotechnologies presented new data at the ASH Annual Meeting demonstrating the impact of its clonoSEQ test in assessing minimal residual disease (MRD) and informing treatment decisions for various blood cancers.
The article highlights the company's advancements in MRD testing with clonoSEQ and its impact on improving blood cancer treatment decisions, indicating a positive outlook for the company's technology and its potential to benefit patients.
Laboratory-Developed Tests (LDTs) World Market Forecast Report to 2028, with Coverage of the Effects of the FDA's New "Medical Devices: Laboratory Developed Tests" Rule, Passed in April 2024
This report analyzes the global market for laboratory-developed tests (LDTs), including the impact of new FDA regulations introduced in 2024. It covers the LDT services market and the market for LDT products sold to clinical laboratories, with a focus on key segments like infectious disease and oncology.
Hematologic Malignancies Testing Markets, 2023-2033: Growing Utilization of Next-Generation Sequencing and AI, Increasing Partnerships, Alliances, and Business Expansions among Key Players
The global hematologic malignancies testing market is expected to grow significantly from $3.54 billion in 2023 to $13.50 billion by 2033, driven by the rising incidence of blood cancers, advancements in diagnostic methods, and strategic partnerships among key players.
The article highlights the increasing demand for hematologic malignancies testing, which could benefit companies like Adaptive Biotechnologies that provide diagnostic solutions in this area.
NeutralZacks Investment Research• N/A
Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data - Zacks Investment Research
Agenus Inc. (AGEN) shares plunged 58.8% after the FDA discouraged the accelerated approval pathway for the company's immunotherapy combination botensilimab (BOT) and balstilimab (BAL) in relapsed/refractory microsatellite stable colorectal cancer. The FDA cited concerns that the observed objective response rate might not translate to a survival benefit.
AGENANIPADPTRAPTAgenusFDAimmunotherapycolorectal cancer
Sentiment note
Adaptive Biotechnologies is mentioned as a top-ranked stock in the biotech sector, with its earnings estimates narrowing in the past 60 days.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
